Written by: Martina Fraga, PharmD
Download Here

This purpose of this PQI is to highlight effective practices to ensure ovarian cancer patients are identified, tested, tracked, and offered a PARP inhibitor when appropriate.

Continue reading Ovarian Cancer: PARP Inhibitor Eligibility

Read More

Written by: Jeremiah Moore, PharmD
Download Here

Selinexor (Xpovio®) is a novel medication for patients with relapsed, refractory multiple myeloma. This PQI will provide background on the novel mechanism of action and discuss effective practices to maximize the use of selinexor therapy.

Continue reading Selinexor Patient Management

Read More

Written by: Tammy McClellan, PharmD
Download Here

The purpose of this PQI is to expand on therapy management of ibrutinib (Imbruvica) when used in combination with obinutuzumab (Gazyva).

Continue reading Ibrutinib expansion with Obinutuzumab

Read More

Written by Isabel Houlzet, PharmD, BCPS, BCOP, Miami Cancer Institute
Download Here

To increase awareness and management of adverse effects related to trifluridine/tipiracil treatment in metastatic colorectal cancer.

Continue reading Trifluridine / Tipiracil for Treatment of Gastric Cancer

Read More

Written by: Linda Frisk, PharmD, Ironwood Cancer and Research Centers
Download Here

The purpose of this PQI is to provide background on PI3K inhibition and review clinical considerations for duvelisib therapy in order to optimize outcomes for cancer patients as well as identifying the patients with malignant lymphoma who may be candidates for duvelisib. Continue reading Duvelisib for Chronic Lymphocytic Leukemia and Follicular Lymphoma

Read More